Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS)

Antimicrob Agents Chemother. 2020 Feb 21;64(3):e01818-19. doi: 10.1128/AAC.01818-19. Print 2020 Feb 21.

Abstract

Antistaphylococcal penicillins such as nafcillin and oxacillin are among the first choices of treatment for severe invasive methicillin-susceptible Staphylococcus aureus (MSSA) infections, although there has been limited safety evaluations between individual agents. Using the FDA Adverse Event Reports System (FAERS), oxacillin was observed to have a lower proportion of reports of acute renal failure (reporting odds ratio [ROR], 5.3 [95% confidence interval {CI}, 3.1 to 9.3] versus 21.3 [95% CI, 15.8 to 28.6], respectively) and hypokalemia (ROR, 0.7 [95% CI, 0.1 to 4.8] versus 11.4 [95% CI, 7.1 to 18.3], respectively) than nafcillin.

Keywords: drug safety; nafcillin; oxacillin; pharmacovigilance.

MeSH terms

  • Acute Kidney Injury / chemically induced*
  • Acute Kidney Injury / diagnosis
  • Acute Kidney Injury / pathology
  • Adverse Drug Reaction Reporting Systems / statistics & numerical data
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / adverse effects*
  • Humans
  • Hypokalemia / chemically induced*
  • Hypokalemia / diagnosis
  • Hypokalemia / pathology
  • Nafcillin / administration & dosage
  • Nafcillin / adverse effects*
  • Odds Ratio
  • Oxacillin / administration & dosage
  • Oxacillin / adverse effects*
  • Patient Safety
  • Staphylococcal Infections / drug therapy*
  • Staphylococcal Infections / microbiology
  • Staphylococcal Infections / pathology
  • Staphylococcus aureus / drug effects
  • Staphylococcus aureus / growth & development
  • Staphylococcus aureus / pathogenicity
  • United States
  • United States Food and Drug Administration

Substances

  • Anti-Bacterial Agents
  • Nafcillin
  • Oxacillin